Nektar Therapeutics (NKTR)

33.02
0.19 0.57
NASDAQ : Health Technology
Prev Close 33.21
Open 33.26
Day Low/High 32.85 / 33.50
52 Wk Low/High 29.22 / 69.76
Volume 780.18K
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 5.88B
EPS 4.00
P/E Ratio 8.56
Div & Yield N.A. (N.A)
Stock Upgrades, Downgrades From TheStreet.com Ratings

Stock Upgrades, Downgrades From TheStreet.com Ratings

Nektar, CTC Media upgraged; Brady, Pinnacle West, CNA Surety downgraded.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Earnings lift Medicis and Nektar, but slam PharmaNet and Osiris.

No Easy Fix for Pfizer

No Easy Fix for Pfizer

It can be done, but it will probably require some tough choices.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Tutogen climbs on a merger deal with Regeneration Technologies.

After Exubera, Uncertainty Reigns

Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.

'Fast Money' Recap: Drug Money

'Fast Money' Recap: Drug Money

Mike Huckman joins the crew as pharmas get close to reporting.

Thursday's Small-Cap Winners & Losers

Thursday's Small-Cap Winners & Losers

Accelr8 Technology revs higher.

Pfizer Drops Sluggish Exubera

The company takes a large charge to leave the inhaled insulin product behind, and earnings plunge.

Wednesday's Health Winners & Losers

Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Sangamo BioSciences climbs on animal study results for an HIV treatment.

One Giant Leap for MannKind

The company will sell $350 million in debt, warrants and stock.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Abraxis Bioscience rises on a quarterly revenue increase.

Pfizer: Exubera's Lung Side Effects Temporary

The drugmaker says patients who stop taking inhaled insulin see lung function return to normal in a month.

Nektar Can't Shake Tempered Exubera

Nektar Can't Shake Tempered Exubera

Its stock will be linked to Exubera's poor launch, at least until some of its other drugs hit the market.

Nektar Slashes Staff

The company will fire 25% of its employees.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Biotech and pharmaceutical stocks were flat, even with Hologic's $6.2 billion deal for Cytyc.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

SuperGen is rising.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Forest Laboratories is weaker.

Nektar Names CEO

Howard W. Robin will take the post.

Expectations Deflated for Alkermes

Expectations Deflated for Alkermes

The company's alcohol-treatment drug did not have the expected impact.

Friday's Analysts' Upgrades and Downgrades

Friday's Analysts' Upgrades and Downgrades

Who made what calls.

Cramer's ' Mad Money' Lightning Round: Not Sipping the Nektar

Cramer's ' Mad Money' Lightning Round: Not Sipping the Nektar

Cramer admits to being wrong on the biopharmaceutical company.

Cramer's 'Mad Money' Recap: Playing Nice With NYSE

Cramer's 'Mad Money' Recap: Playing Nice With NYSE

Cramer says mea culpa about not being an NYSE fan and also gets a kick out of the Giants' Jay Feely.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Novogen is on the rise.

Friday's Analysts' Upgrades and Downgrades

Friday's Analysts' Upgrades and Downgrades

Who made what calls.

Cramer's 'Mad Money Lightning Round': Chipotle on Its Shoulder

Cramer's 'Mad Money Lightning Round': Chipotle on Its Shoulder

Cramer prefers McDonald's to the Mexican fast-food outfit.

Novo Nordisk Sues Pfizer

Novo Nordisk Sues Pfizer

The Danish company alleges patent infringement over Exubera.

Pfizer Postpones Exubera Launch

The inhaled insulin will go on sale in September, a few weeks later than planned.

Exubera Success May Hinge on Usability

Exubera Success May Hinge on Usability

Pfizer and Nektar will know soon enough if diabetics are ready to make the switch from injections to inhaled insulin.

Pfizer Seeks Pricing Perfection

Pfizer Seeks Pricing Perfection

The cost of the inhaled insulin Exubera hasn't been disclosed, but the drug hits the market in July.

TheStreet Quant Rating: C (Hold)